Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Targeting H3K4 trimethylation in Huntington disease.

Vashishtha M, Ng CW, Yildirim F, Gipson TA, Kratter IH, Bodai L, Song W, Lau A, Labadorf A, Vogel-Ciernia A, Troncosco J, Ross CA, Bates GP, Krainc D, Sadri-Vakili G, Finkbeiner S, Marsh JL, Housman DE, Fraenkel E, Thompson LM.

Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):E3027-36. doi: 10.1073/pnas.1311323110. Epub 2013 Jul 19.

2.

The X-linked mental retardation gene SMCX/JARID1C defines a family of histone H3 lysine 4 demethylases.

Iwase S, Lan F, Bayliss P, de la Torre-Ubieta L, Huarte M, Qi HH, Whetstine JR, Bonni A, Roberts TM, Shi Y.

Cell. 2007 Mar 23;128(6):1077-88. Epub 2007 Feb 22.

3.

The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.

Niu X, Zhang T, Liao L, Zhou L, Lindner DJ, Zhou M, Rini B, Yan Q, Yang H.

Oncogene. 2012 Feb 9;31(6):776-86. doi: 10.1038/onc.2011.266. Epub 2011 Jul 4.

4.

Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain.

Ginés S, Bosch M, Marco S, Gavaldà N, Díaz-Hernández M, Lucas JJ, Canals JM, Alberch J.

Eur J Neurosci. 2006 Feb;23(3):649-58.

PMID:
16487146
5.

Altered histone monoubiquitylation mediated by mutant huntingtin induces transcriptional dysregulation.

Kim MO, Chawla P, Overland RP, Xia E, Sadri-Vakili G, Cha JH.

J Neurosci. 2008 Apr 9;28(15):3947-57. doi: 10.1523/JNEUROSCI.5667-07.2008.

6.

Modulation of nucleosome dynamics in Huntington's disease.

Stack EC, Del Signore SJ, Luthi-Carter R, Soh BY, Goldstein DR, Matson S, Goodrich S, Markey AL, Cormier K, Hagerty SW, Smith K, Ryu H, Ferrante RJ.

Hum Mol Genet. 2007 May 15;16(10):1164-75. Epub 2007 Apr 2.

PMID:
17403718
7.

The histone H3K4 demethylase SMCX links REST target genes to X-linked mental retardation.

Tahiliani M, Mei P, Fang R, Leonor T, Rutenberg M, Shimizu F, Li J, Rao A, Shi Y.

Nature. 2007 May 31;447(7144):601-5. Epub 2007 Apr 29.

PMID:
17468742
8.

Balancing of histone H3K4 methylation states by the Kdm5c/SMCX histone demethylase modulates promoter and enhancer function.

Outchkourov NS, Muiño JM, Kaufmann K, van Ijcken WF, Groot Koerkamp MJ, van Leenen D, de Graaf P, Holstege FC, Grosveld FG, Timmers HT.

Cell Rep. 2013 Apr 25;3(4):1071-9. doi: 10.1016/j.celrep.2013.02.030. Epub 2013 Mar 28.

9.

Specific promoter deacetylation of histone H3 is conserved across mouse models of Huntington's disease in the absence of bulk changes.

Guiretti D, Sempere A, Lopez-Atalaya JP, Ferrer-Montiel A, Barco A, Valor LM.

Neurobiol Dis. 2016 May;89:190-201. doi: 10.1016/j.nbd.2016.02.004. Epub 2016 Feb 3.

PMID:
26851501
10.

CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice.

Apostol BL, Simmons DA, Zuccato C, Illes K, Pallos J, Casale M, Conforti P, Ramos C, Roarke M, Kathuria S, Cattaneo E, Marsh JL, Thompson LM.

Mol Cell Neurosci. 2008 Sep;39(1):8-20. doi: 10.1016/j.mcn.2008.04.007. Epub 2008 Apr 24.

PMID:
18602275
11.

Drosophila Set1 is the major histone H3 lysine 4 trimethyltransferase with role in transcription.

Ardehali MB, Mei A, Zobeck KL, Caron M, Lis JT, Kusch T.

EMBO J. 2011 Jun 21;30(14):2817-28. doi: 10.1038/emboj.2011.194.

12.

Hypoxia induces trimethylated H3 lysine 4 by inhibition of JARID1A demethylase.

Zhou X, Sun H, Chen H, Zavadil J, Kluz T, Arita A, Costa M.

Cancer Res. 2010 May 15;70(10):4214-21. doi: 10.1158/0008-5472.CAN-09-2942. Epub 2010 Apr 20.

13.

Early defect of transforming growth factor β1 formation in Huntington's disease.

Battaglia G, Cannella M, Riozzi B, Orobello S, Maat-Schieman ML, Aronica E, Busceti CL, Ciarmiello A, Alberti S, Amico E, Sassone J, Sipione S, Bruno V, Frati L, Nicoletti F, Squitieri F.

J Cell Mol Med. 2011 Mar;15(3):555-71. doi: 10.1111/j.1582-4934.2010.01011.x.

14.

Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models.

Sontag EM, Lotz GP, Agrawal N, Tran A, Aron R, Yang G, Necula M, Lau A, Finkbeiner S, Glabe C, Marsh JL, Muchowski PJ, Thompson LM.

J Neurosci. 2012 Aug 8;32(32):11109-19.

15.

ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease.

Ryu H, Lee J, Hagerty SW, Soh BY, McAlpin SE, Cormier KA, Smith KM, Ferrante RJ.

Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):19176-81. Epub 2006 Dec 1.

16.

Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease.

Chan EY, Luthi-Carter R, Strand A, Solano SM, Hanson SA, DeJohn MM, Kooperberg C, Chase KO, DiFiglia M, Young AB, Leavitt BR, Cha JH, Aronin N, Hayden MR, Olson JM.

Hum Mol Genet. 2002 Aug 15;11(17):1939-51.

PMID:
12165556
17.
18.

Huntington disease arises from a combinatory toxicity of polyglutamine and copper binding.

Xiao G, Fan Q, Wang X, Zhou B.

Proc Natl Acad Sci U S A. 2013 Sep 10;110(37):14995-5000. doi: 10.1073/pnas.1308535110. Epub 2013 Aug 26.

19.

Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice.

Bradford J, Shin JY, Roberts M, Wang CE, Sheng G, Li S, Li XJ.

J Biol Chem. 2010 Apr 2;285(14):10653-61. doi: 10.1074/jbc.M109.083287. Epub 2010 Feb 9.

20.

Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.

Jia H, Pallos J, Jacques V, Lau A, Tang B, Cooper A, Syed A, Purcell J, Chen Y, Sharma S, Sangrey GR, Darnell SB, Plasterer H, Sadri-Vakili G, Gottesfeld JM, Thompson LM, Rusche JR, Marsh JL, Thomas EA.

Neurobiol Dis. 2012 May;46(2):351-61.

Supplemental Content

Support Center